Hims & Hers Introduces Generic Semaglutide Offering in Canada

Hims & Hers launched generic semaglutide in Canada through its telehealth platform. The offering aims to expand affordable access to GLP-1 treatments and weight management care.  The move comes as competition and regulatory scrutiny around semaglutide products continue to grow.

Hims & Hers Introduces Generic Semaglutide Offering in Canada

Hims & Hers is expanding its GLP-1 offerings in Canada by introducing generic semaglutide through its direct-to-consumer telehealth platform following the loss of Novo Nordisk’s Canadian patent protection for Ozempic and Wegovy. Eligible customers in Canada will be able to access personalized weight management plans that may include generic semaglutide starting at CAD 149 per month, along with ongoing support from care teams focused on areas such as nutrition, sleep and physical activity. The move is aimed at increasing affordability and access to GLP-1 treatments as demand for weight-loss and metabolic health medications continues to rise.

The launch comes amid broader shifts in the Canadian semaglutide market after Health Canada approved the country’s first generic version earlier this year, with additional applications currently under review. Hims & Hers has been rapidly expanding its telehealth and wellness services across areas including weight management, mental health, primary care and women’s health, positioning itself as a consumer-focused healthcare platform. By offering lower-cost generic options, the company is seeking to capitalize on growing demand while differentiating itself through bundled virtual care and ongoing patient support.

The expansion also follows increased regulatory and legal scrutiny around compounded and unapproved GLP-1 products sold online and through telehealth providers. Earlier this year, Novo Nordisk filed and later dropped a patent infringement lawsuit against Hims & Hers before the companies announced a strategic partnership related to FDA-approved GLP-1 therapies. Against this backdrop, Hims & Hers’ Canadian generic semaglutide launch reflects the evolving competitive landscape around obesity and diabetes treatments, where affordability, accessibility and regulatory compliance are becoming increasingly important.